High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma
- Yanmiao Huo†1,
- Minwei Yang†1,
- Wei Liu†1,
- Jianyu Yang†1,
- Xueliang Fu1,
- Dejun Liu1,
- Jiao Li1,
- Junfeng Zhang1,
- Rong Hua1Email author and
- Yongwei Sun1Email author
© Huo et al. 2015
Received: 18 May 2015
Accepted: 6 August 2015
Published: 22 August 2015
Discoidin domain receptors 1 (DDR1), a subtype of DDRs, has been reported as a critical modulator of cellular morphogenesis, differentiation, migration and invasion.
Methods and results
In this study, we investigated the expression of DDR1 and its clinical association in Chinese patients with pancreatic ductal adenocarcinoma (PDAC). Across a cohort of 30 patients, we examined DDR1 expression in paired PDAC and corresponding adjacent non-tumor tissues by real-time quantitative PCR (RT-qPCR), or western blotting. DDR1 expression is significantly higher in PDAC, as compared to normal adjacent tissue, confirming results from the Oncomine databases. We validated DDR1 expression by immunohistochemistry across a non-overlapping cohort of 205 PDAC specimens. Kaplan-Meier survival curves indicate that increased expression of DDR1 is associated with a poor prognosis in PDAC patients (P = 0.013). Multivariate Cox regression analysis identified DDR1 expression, age, N classification and liver metastasis as independent prognostic factors in PDAC.
This study demonstrated that DDR1 can well serve as a novel prognostic biomarker in PDAC.
KeywordsDDR1 Pancreatic ductal adenocarcinoma Prognosis
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease and the fourth most common disease-related mortality worldwide [1, 2]. The 5-year survival is approximately 6 %, and only 20 % of patients present with resectable disease [3, 4]. Few PDAC cases (less than 10 %) are diagnosed at early stages , largely due to the absence of specific symptoms, and as such patients often present with advanced stage disease. Hence, the identification of novel prognostic indicators has become a major topic of interest to the PDAC research community at large.
The discoidin domain receptor 1 (DDR1) belongs to a subfamily of Receptor tyrosine kinases (RTKs) characterized by the presence of an extracellular discoidin homology domain that function to modulates cell proliferation and differentiation. DDRs are non-integrin collagen receptors composed of two types, DDR1 and DDR2, independently activated by receptor-specific collagens binding at the discoidin domain . DDR1 can be alternatively spliced into five isoforms (DDR1a-e). Recently, studies have suggested DDR1 participates in several critical cell processes including: adhesion, migration, proliferation, and invasion [7–9]. Moreover, expression of DDR1 is known to be dysregulated in multiple human cancers such as lung, breast, hepatic, and ovary cancers, suggesting a previously unappreciated role of DDR1 in tumor formation and progression [10–13]. In PDACs, however, the role of DDR1 remains to be uncharacterized.
In this retrospective study, we examined the expression pattern of DDR1 at the mRNA and protein level and explored the relationship of DDR1 expression with clinicopathologic parameters, including overall survival. We found that the expression of DDR1 was associated with poor prognosis of Chinese PDAC patients.
Materials and methods
This research was approved by the Ethics Committee of Ren Ji hospital, School of Medicine, Shanghai Jiao Tong University, and written informed consent was obtained from each patient involved in this study.
Patients and tissue specimens
Association between DDR1 expression and clinicopathologic features in patients with PDAC
(n = 126)
(n = 79)
≤ 2 cm
> 2 cm
RNA extraction and real-time quantitative PCR (RT-qPCR)
Total RNA from primary tumor and adjacent non-tumor tissue samples was isolated with Trizol reagent (Takara, Japan), and reversely transcribed through PrimeScript RT-qPCR kit (Takara, Japan) according to the manufacturer’s instructions . RT-qPCR was performed using a 7500 RT-qPCR system (Applied Biosystems, Inc. USA) with a 15-μl PCR mix containing 0.5 μl of cDNA, 7.5 μl of 2*SYBR Green master mix (Invitrogen, Carlsbad, California, USA), and 200 nM of the appropriate primers (Invitrogen, Carlsbad, California, USA). Primer sequences set for DDR1 detection were as follows: forward primer: 5’-GCGTCTGTCTGCGGGTAGAG-3’, reverse primer: 5’-ACGGCCTCAGATAAATACATTGTCT-3’. The relative levels of mRNA expression were calculated based on the difference between amplification of DDR1 and β-actin RNA (forward: 5’-ACTCGTCATACTCCTGCT-3’, reverse: 5’- GAAACTACCTTCAACTCC-3’) using the 2-ΔΔct method . To minimize technical (run-to-run) variation between the samples, all samples were analyze d in the same run for both target genes and reference genes. All experiments were performed three times with three technical replicates.
Western blotting analysis
Western blotting was performed as previously described . The DDR1 antibody was purchased from Proteintech Inc. and species-specific secondary antibody was purchased from Cell Signaling, Beverly, MA. Bound secondary antibodies were detected by Odyssey imaging system (LI-COR Biosciences, Lincoln, NE).
Tissue microarray (TMA) construction
Tissue microarrays (TMA) were constructed using diameter of 1.5-mm cores including 205 cases of matched tumor and non-tumor tissues specimens. After screening and marking representative spots of tissues, the tissues were punched out and squeezed into the paraffin array blocks.
Immunohistochemical (IHC) staining and scoring
Immunohistochemical staining was performed on a tissue microarray (TMA) containing 205 paired PDAC samples as previous described . Scoring was calculated according to the sum of the percentage of positively stained tumor cells: 0–5 % scored 0; 6 %–35 % scored 1; 36 %–70 % scored 2; more than 70 % scored 3 and the staining intensity: no staining scored 0, weakly staining scored 1, moderately staining scored 2 and strongly staining scored 3, respectively. The final score was designated as low or high expression group using the percentage of cells staining positive multiplied by the staining intensity as follows: “-” for a score of 0–1, “+” for a score of 2–3, “++” for a score of 4–6 and “+++” for a score of > 6; low expression was defined as a total score < 4 and high expression with a total score ≥ 4. These scores were determined independently by two senior pathologists. The scoring by the pathologists was done in a blinded manner.
The postoperative follow-up included clinical and laboratory examinations. OS, a measure of prognosis, was defined as the time from the date of surgery to the date of death or the last follow-up examination.
All statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 (San Diego, CA) software. DDR1 mRNA in the tumor and adjacent non-tumor tissue samples were compared using a paired-samples t test. The Chi-square test and Fisher’s exact probability method was used to analyze the relationship between DDR1 expression and clinicopathological characteristics. Survival curves were evaluated using the Kaplan-Meier method, and differences between survival curves were tested by the log-rank test. Cox proportional hazards regression model was used to examine univariate and multivariate hazard ratios for the study variables. Only significantly different variables in univariate analysis including DDR1 expression level, Age, N classification, Liver metastasis were entered into the next multivariate analysis . A two-sided P-value < 0.05 was considered statistically significant.
DDR1 is transcriptionally upregulated in PDAC
DDR1 expression at protein level in PDAC
Correlation of DDR1 expression with clinicopathological features of PDAC
To determine the relationship between DDR1 expressions with the clinicopathological features of PDAC, the IHC staining of DDR1 levels were statistically evaluated by the Chi-square tests. The clinicopathologic parameters in PDAC included: age, gender, clinical stage, liver metastasis, vascular invasion and differentiation status. As shown in Table 1, no significant differences were found between DDR1 expression and any other parameters.
Correlation of DDR1 expression and prognosis in PDAC patients
Univariate and multivariate analyses
Univariate and multivariate analyses of prognostic parameters for survival in patients with pancreatic ductal adenocarcinoma (PDAC)
95 % CI
95 % CI
DDR1 (low vs.high)
Age (<65 vs. ≥65)
Gender (male vs. female)
Tumor location (head vs. body/tail)
Size (≤2 cm vs. >2 cm)
Tumor differentiation (well vs. moderate/poor)
T classification (T1 vs. T2 vs. T3 vs. T4)
AJCC stage (I vs. II vs. III vs. IV)
N classification (absent vs. present)
Liver metastasis (absent vs. present)
Vascular invasion (absent vs. present)
Previously studies have identified DDR1 is overexpressed in various human invasive tumors including lung, breast, hepatic, and ovary cancers, highlighting its possible role in tumor initiation, maintenance or progression [10–13]. In the present study, DDR1 expression and its association with clinicopathological features including prognosis were investigated across a cohort of Chinese PDAC patients.
We determined that DDR1 expression was increased in Chinese PDAC patients at both the mRNA and protein level. These findings are supported by non-overlapping data from an Oncomine database, which highlights the same trends in PDAC. We expanded our analysis to a non-overlapping cohort of 205 patients and determined that DDR1 expression was upregulated in 126/205 PDAC specimens. Elevated DDR1 expression has also been reported in: (i) 52.2 % of hepatocellular carcinoma samples ; (ii) 61.0 % of non-small cell lung cancer ; and (iii) 63 % of serous ovarian cancer tissues . The overexpression of DDR1 in these different human cancers support the hypothesis that DDR1 may impact tumorigenesis and/or tumor progression.
Previous studies indicated that DDR1 could promote tumor progression by inducing cell adhesion and differentiation, which might be due to: (i) coexpressing with adhesion molecules ; (ii) promoting epithelial-mesenchymal transition (EMT) [21, 23]; (iii) participating in functional interaction of Notch1 and NF-κB pathway [24, 25]. Furthermore, survival analysis in our study revealed that PDAC patients with high DDR1 expression levels had significantly shorter survival times than those with low expression levels. Univariate analyses showed that increased DDR1 expression was significantly associated with the overall survival rate in PDAC patients. Multivariate analysis demonstrated that DDR1 expression, together with some traditional prognostic factors, such as age, N stage and liver metastasis, were independent risk factors in the prognosis of PDAC patients. These results suggested that DDR1 may represent a novel prognostic marker for PDAC patients.
The precise molecular mechanisms through which DDR1’s impacts on tumor development and differentiation have yet to be elucidated. DDR1 presents 15 tyrosine residues in cell’s cytoplasmic regions, which are potential sites for phosphorylation and receptor activation by different types of collagens [6, 12, 26]. It has been shown that over-expression of DDR1 increased the migration and invasion of hepatoma cells in vitro, which implicated a role of DDR1 in tumor progression and metastatic dissemination . Reduced or absent DDR1 expression in vivo leads to defects in placental implantation and development of mammary gland , while Miao et al. demonstrated that DDR1 expression promoted epithelial-to-mesenchymal transition and contributed to non-small-cell lung cancer cells migration and invasion. The signaling pathways contributed by DDR1 upon cell-matrix interaction remain elusive and need further investigation.
In conclusion, this study demonstrated that DDR1 might serve as a novel prognostic biomarker in PDAC. Importantly, the molecular mechanisms underlying the relationship described above require clarification. Further studies are needed to investigate the molecular pathways involved in the regulation of DDR1, to improve our understanding and explore the possible therapies.
This study was supported by the National Natural Science Foundation of China (Grant No. 81401931) and the Young Medical Doctors Training and Funding Project of Shanghai Municipal Commission of Health and Family Planning. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72. doi:https://doi.org/10.1038/nrclinonc.2009.236.View ArticlePubMedGoogle Scholar
- Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB Off J Int Hepato Pancreato Biliary Assoc. 2008;10(1):58–62. doi:https://doi.org/10.1080/13651820701883148.View ArticleGoogle Scholar
- Jiang SH, He P, Ma MZ, Wang Y, Li RK, Fang F, et al. PNMA1 promotes cell growth in human pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 2014;7(7):3827–35.PubMed CentralPubMedGoogle Scholar
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:https://doi.org/10.3322/caac.21208.View ArticlePubMedGoogle Scholar
- Remmers N, Bailey JM, Mohr AM, Hollingsworth MA. Molecular pathology of early pancreatic cancer. Cancer Biomarkers Section Dis Markers. 2010;9(1-6):421–40. doi:https://doi.org/10.3233/CBM-2011-0168.Google Scholar
- Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal. 2006;18(8):1108–16. doi:https://doi.org/10.1016/j.cellsig.2006.02.012.View ArticlePubMedGoogle Scholar
- Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol J Int Soc Matrix Biol. 2014;34:185–92. doi:https://doi.org/10.1016/j.matbio.2013.12.002.View ArticleGoogle Scholar
- Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol. 2004;164(5):1575–85. doi:https://doi.org/10.1016/S0002-9440(10)63716-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Valencia K, Ormazabal C, Zandueta C, Luis-Ravelo D, Anton I, Pajares MJ, et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(4):969–80. doi:https://doi.org/10.1158/1078-0432.CCR-11-1686.View ArticleGoogle Scholar
- Yang SH, Baek HA, Lee HJ, Park HS, Jang KY, Kang MJ, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep. 2010;24(2):311–9.PubMedGoogle Scholar
- Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010;9:227. doi:https://doi.org/10.1186/1476-4598-9-227.PubMed CentralView ArticlePubMedGoogle Scholar
- Castro-Sanchez L, Soto-Guzman A, Guaderrama-Diaz M, Cortes-Reynosa P, Salazar EP. Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells. Clin Exp Metastasis. 2011;28(5):463–77. doi:https://doi.org/10.1007/s10585-011-9385-9.View ArticlePubMedGoogle Scholar
- Quan J, Yahata T, Adachi S, Yoshihara K, Tanaka K. Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer. Int J Mol Sci. 2011;12(2):971–82. doi:https://doi.org/10.3390/ijms12020971.PubMed CentralView ArticlePubMedGoogle Scholar
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. doi:https://doi.org/10.1056/NEJMoa1304369.View ArticleGoogle Scholar
- Kang M, Jiang B, Xu B, Lu W, Guo Q, Xie Q, et al. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett. 2013;330(1):11–21. doi:https://doi.org/10.1016/j.canlet.2012.11.015.View ArticlePubMedGoogle Scholar
- Yang JY, Sun YW, Liu DJ, Zhang JF, Li J, Hua R. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am J Cancer Res. 2014;4(6):663–73.PubMed CentralPubMedGoogle Scholar
- Liang X, Sun S, Zhang X, Wu H, Tao W, Liu T et al. Expression of ribosome-binding protein 1 correlates with shorter survival in Her-2 positive breast cancer. Cancer science. 2015. doi:10.1111/cas.12666Google Scholar
- Li J, Yang XM, Wang YH, Feng MX, Liu XJ, Zhang YL, et al. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. J Hepatol. 2014;60(6):1225–34. doi:https://doi.org/10.1016/j.jhep.2014.02.025.View ArticlePubMedGoogle Scholar
- Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R et al. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. 2015. doi:10.1136/gutjnl-2015-309372Google Scholar
- Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, Schmiegel W, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene. 2005;24(44):6626–36. doi:https://doi.org/10.1038/sj.onc.1208804.View ArticlePubMedGoogle Scholar
- Miao LY, Zhu SH, Wang YS, Li Y, Ding JJ, Dai JH, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med Oncol. 2013;30(3):626. doi:https://doi.org/10.1007/S12032-013-0626-4. doi:Unsp.View ArticlePubMedGoogle Scholar
- Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(13):4427–36. doi:https://doi.org/10.1158/1078-0432.CCR-04-0073.View ArticleGoogle Scholar
- Maeyama M, Koga H, Selvendiran K, Yanagimoto C, Hanada S, Taniguchi E, et al. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer. 2008;113(10):2823–31. doi:https://doi.org/10.1002/cncr.23900.View ArticlePubMedGoogle Scholar
- Lu KK, Trcka D, Bendeck MP. Collagen stimulates discoidin domain receptor 1-mediated migration of smooth muscle cells through Src. Cardiovas Pathol Off J Soc Cardiovas Pathol. 2011;20(2):71–6. doi:https://doi.org/10.1016/j.carpath.2009.12.006.View ArticleGoogle Scholar
- Curat CA, Vogel WF. Discoidin domain receptor 1 controls growth and adhesion of mesangial cells. J Am Soc Nephrol JASN. 2002;13(11):2648–56.View ArticlePubMedGoogle Scholar
- Vogel W. Discoidin domain receptors: structural relations and functional implications. FASEB J Off Publ Federation Am Soc Exp Biol. 1999;13(Suppl):S77–82.Google Scholar
- Park HS, Kim KR, Lee HJ, Choi HN, Kim DK, Kim BT, et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase. Oncol Rep. 2007;18(6):1435–41.PubMedGoogle Scholar
- Vogel WF, Aszodi A, Alves F, Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol Cell Biol. 2001;21(8):2906–17. doi:https://doi.org/10.1128/MCB.21.8.2906-2917.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- McIntyre CA, Winter JM. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42(1):19–27. doi:https://doi.org/10.1053/j.seminoncol.2014.12.003.View ArticlePubMedGoogle Scholar